Diasorin S.p.a. · MIL:DIA
Diasorin — Investor Day (2012)
7 slides from Diasorin's investor day presentation, 2012
Slide 1: 2012-2015 Strategy
2012-2015 STRATEGY
Slide 2: Business Plan Revenues Main Assumptions
BUSINESS PLAN REVENUES MAIN ASSUMPTIONS VITAMIN D SALES LIAISON SALES MUREX SALES NAT 2011-2015 (EX VITAMIN D) 2011-2015 GENERATING BY 2015 CAGR 2011-2015 CAGR €/MLN SALES 2.2% 21% 7% 15-20 PRICE EROSION IN THE US LAUNCH OF BLOOD FOCUSING AGAINST OTHER WITH THE INITIAL INFECTIOUS AND EUROPE CAGR ~ 7
Slide 3: Business Plan Main Margin Assumptions
BUSINESS PLAN MAIN MARGIN ASSUMPTIONS GROSS MARGINS FLAT ON 2011: >70% PRESSURE IN VITAMIN D PRICES SCALE ECONOMIES IN MANUFACTURING PLANTS REDUCED ROYALTY RATES OPERATING MARGINS: SUSTAINABLE THROUGHOUT THE PERIOD ADDITIONAL INVESTMENT COMPENSATED THROUGH OPERATING LEVERAGE DIASORIN: RIDING A NEW B
Slide 4: DiaSorin Additional Revenues Breakdown
DIASORIN ADDITIONAL REVENUES BREAKDOWN MARKET VALUE WW DIASORIN REVENUES DIASORIN STRATEGY ¤/MLN MARKET SHARE POTENTIAL ¤/MLN 2011E 2015E INFECTIOUS DISEASE WW 850 10% ~ 15% 60-70 Liaison XL to: (EX HEPATITIS AND RETROVIRUSES) - access mid-large clinical labs - accelerate plate conversion - consolid
Slide 5: 2012-2015 Guidance
2012-2015 GUIDANCE ¤/MLN FY 2011 E FY 2015 E SALES ~ 450 630-680 EBITDA ~ 200 > 280 1 0% 5 E~ 01 –2 01 1E G R2 9 % CA 5 E~ 01 –2 01 1E G R2 CA 2011 E 2015 E SALES EBITDA DIASORIN: RIDING A NEW BUSINESS WAVE
Slide 6: Future M&A
FUTURE M&A DIASORIN STRONG BALANCE SHEET AND CASH GENERATION ALLOW US TO LOOK FOR FUTURE ACQUISITIONS IN TERMS OF: CUMULATED FREE CASH FLOW @2015E: ~ 600 CONTENTS EBITDA FY 2015E: > 280 TECHNOLOGIES PRODUCTS DEVELOPMENT OF NET DEBT AND EBITDA NET DEBT / EBITDA RATIO 0.35x 0.25x 0.15x 0.05x (0.05x) (
Slide 7: Value Sustainable Growth
RIDING A NEW BUSINESS WAVE VALUE SUSTAINABLE GROWTH INNOVATION QUALITY COMMITMENT TO CLIENTS